|  | Cancer | Lymphoma

Mantle Cell Lymphoma Relapse: Navigating Next Steps and Treatment Options

Mantle Cell Lymphoma (MCL) frequently relapses despite initial response. Management of relapsed/refractory (R/R) MCL is highly individualized based on multiple clinical and personal factors.

Key Decision Factors

  • Prior therapies received (BTK inhibitor, chemoimmunotherapy, transplant)
  • Duration of prior remission (shorter remission suggests more aggressive biology)
  • Patient age, fitness, and comorbidities
  • Disease tempo (indolent vs. blastoid/pleomorphic variant)
  • Genetic markers (TP53 mutation, complex karyotype = poorer prognosis)
  • Patient goals and preferences

Treatment Options for Relapsed MCL

BTK Inhibitors (If Not Previously Used or After Chemoimmunotherapy)

  • Ibrutinib (first-in-class): Approved for R/R MCL; ~68% overall response rate (ORR)
  • Acalabrutinib (second-gen): Better cardiac safety profile
  • Zanubrutinib (second-gen): High CNS penetration; favorable safety
  • Pirtobrutinib (non-covalent): Active after covalent BTK inhibitor failure (~50% ORR)

BCL-2 Inhibition

  • Venetoclax: Combined with BTKi or rituximab; promising in R/R settings

PI3K Inhibitors

  • Idelalisib, Duvelisib, Copanlisib: Approved for R/R MCL; require monitoring for infection, colitis, hepatotoxicity

Immunotherapy

  • CAR T-cell therapy (Brexucabtagene autoleucel): FDA-approved for R/R MCL; ~90% ORR, ~60% complete response; CRS/ICANS risks
  • Bispecific antibodies (epcoritamab, glofitamab): Emerging off-trial access

Other Modalities

  • Chemoimmunotherapy: Bendamustine-rituximab, R-CHOP, R-DHAP (if chemo-sensitive, long prior remission)
  • Radiation: Consolidation for localized relapse; palliation
  • Allogeneic Stem Cell Transplant: Curative potential; high transplant-related mortality; considered for fit patients with high-risk features
  • Clinical Trials: Strongly encouraged; novel agents (BTK degraders, CDK9 inhibitors, novel immunotherapies)

Treatment Goals

  • Disease control and symptom relief
  • Quality of life preservation
  • Deep responses (complete remission) when achievable
  • Sequencing therapies to maximize longevity

Multidisciplinary discussion at a lymphoma center of excellence optimizes sequencing and access to novel therapies.

Lymphoma - Related Articles